| Medical and Health Sciences | Lifetime | 388 | US 210 | 99.98 |
| Biological Sciences | Lifetime | 728 | US 403 | 99.91 |
| Oncology | Lifetime | 6 | US 4 | 99.99 |
| Cancer Research | Lifetime | 5 | US 4 | 99.97 |
| Pulmonary and Respiratory Medicine | Lifetime | 277 | US 151 | 99.65 |
| Genetics | Lifetime | 560 | US 301 | 98.68 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 517 | US 289 | 98.69 |
| Pathology and Forensic Medicine | Lifetime | 342 | US 164 | 98.68 |
| Dermatology | Lifetime | 801 | US 325 | 90.79 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 477 | US 158 | 94.84 |
| Cancer Research | 2021-2025 | 145 | US 52 | 92.63 |
| Oncology | 2021-2025 | 584 | US 256 | 91.45 |
| Cancer Treatment and Pharmacology | Lifetime | 1 | US 1 | 99.99 |
| Breast Cancer Treatment Studies | Lifetime | 1 | US 1 | 99.99 |
| HER2/EGFR in Cancer Research | Lifetime | 1 | US 1 | 99.98 |
| Cancer Diagnosis and Treatment | Lifetime | 3 | US 2 | 99.89 |
| Breast Lesions and Carcinomas | Lifetime | 3 | US 2 | 99.92 |
| Advanced Breast Cancer Therapies | Lifetime | 4 | US 3 | 99.94 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 2 | US 1 | 99.78 |
| Cancer Genomics and Diagnostics | Lifetime | 82 | US 52 | 99.77 |
| Cancer-related Molecular Pathways | Lifetime | 66 | US 43 | 99.65 |
| Chemotherapy-related skin toxicity | Lifetime | 9 | US 6 | 99.43 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 79 | US 47 | 99.29 |
| Cancer Cells and Metastasis | Lifetime | 101 | US 56 | 99.44 |
| BRCA gene mutations in cancer | Lifetime | 54 | US 29 | 99.34 |
| Neutropenia and Cancer Infections | Lifetime | 47 | US 29 | 99.42 |
| Bone health and treatments | Lifetime | 107 | US 54 | 99.39 |
| Estrogen and related hormone effects | Lifetime | 164 | US 108 | 99.24 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 429 | US 253 | 99.21 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 93 | US 57 | 99.11 |
| Metastasis and carcinoma case studies | Lifetime | 180 | US 23 | 98.27 |
| Peptidase Inhibition and Analysis | Lifetime | 426 | US 200 | 98.41 |
| Global Cancer Incidence and Screening | Lifetime | 229 | US 122 | 98.68 |
| Economic and Financial Impacts of Cancer | Lifetime | 138 | US 94 | 98.08 |
| Lung Cancer Research Studies | Lifetime | 372 | US 169 | 98.57 |
| Lung Cancer Treatments and Mutations | Lifetime | 671 | US 315 | 98.59 |
| Management of metastatic bone disease | Lifetime | 134 | US 69 | 98.02 |
| Colorectal Cancer Treatments and Studies | Lifetime | 434 | US 196 | 98.70 |
| Multiple and Secondary Primary Cancers | Lifetime | 172 | US 74 | 97.96 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 582 | US 270 | 98.50 |
| Male Breast Health Studies | Lifetime | 15 | US 9 | 97.61 |
| Brain Metastases and Treatment | Lifetime | 232 | US 146 | 98.24 |
| Cancer Risks and Factors | Lifetime | 195 | US 101 | 98.49 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 810 | US 400 | 98.32 |
| Advances in Oncology and Radiotherapy | Lifetime | 128 | US 71 | 96.66 |
| Lymphoma Diagnosis and Treatment | Lifetime | 946 | US 408 | 97.89 |
| Breast Implant and Reconstruction | Lifetime | 243 | US 158 | 97.21 |
| Gene expression and cancer classification | Lifetime | 402 | US 227 | 96.57 |
| Cancer and Skin Lesions | Lifetime | 470 | US 228 | 96.47 |
| Medical Imaging and Pathology Studies | Lifetime | 911 | US 400 | 95.93 |
| PARP inhibition in cancer therapy | Lifetime | 712 | US 308 | 92.74 |
| Breast Cancer Treatment Studies | 2021-2025 | 180 | US 63 | 97.87 |
| Advanced Breast Cancer Therapies | 2021-2025 | 119 | US 42 | 98.04 |
| HER2/EGFR in Cancer Research | 2021-2025 | 154 | US 58 | 97.69 |
| Cancer Treatment and Pharmacology | 2021-2025 | 203 | US 68 | 96.01 |
| Breast Lesions and Carcinomas | 2021-2025 | 268 | US 84 | 88.74 |
| Cancer-related Molecular Pathways | 2021-2025 | 466 | US 166 | 81.58 |
